Finch Therapeutics Group, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Finch Therapeutics has announced its decision to delist from the Nasdaq and deregister its common stock with the SEC, citing cost savings and compliance burdens.
Finch Therapeutics and the University of Minnesota won a patent infringement case against Ferring Pharmaceuticals, securing a $25 million upfront payment and $0.815 million in running royalties.
Finch Therapeutics Group, Inc. will be delisted from the Nasdaq Stock Market and its shares will begin trading on the over-the-counter market after the company was deemed to no longer have an operating business.
Finch Therapeutics has received an additional delisting notice from Nasdaq due to its failure to maintain the required market value of publicly held shares, and is requesting a transfer to the Nasdaq Capital Market.
Finch Therapeutics has been notified by Nasdaq that it is not in compliance with audit committee composition requirements following a director's resignation.
Finch Therapeutics has been notified by Nasdaq that it may be delisted due to concerns about its operating business status, prompting an appeal from the company.